# US 2008/0306071 A1 · Substituted piperidine compounds and methods of their use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0306071 A1
- Document ID: US20080306071A1
- Status: Published application
- Kind: A1
- Application number: 12/110,915
- Filed: 2008-04-28
- Published: 2008-12-11
- Earliest claimed: 2003-03-17
- Assignees: Adolor Corporation
- Inventors: Roland Ellwood Dolle; Bertrand Le Bourdonnec
- Web page: https://patentgrep.com/patent/US20080306071A1

## CPC

- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- C07D 211/34: with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 211/58: attached in position 4
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 401/10: linked by a carbon chain containing aromatic rings
- C07D 401/14: containing three or more hetero rings
- C07D 409/14: containing three or more hetero rings
- C07D 413/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Novel 3,4-disubstituted-4-aryl-piperidine compounds are disclosed. Pharmaceutical compositions containing the 3,4-disubstituted-4-aryl-piperidine compounds and methods of their pharmaceutical uses are also disclosed. The compounds disclosed are useful, inter alia, as antagonists of opioid receptors.

## Claims

### Claim 1

A compound of formula I:
wherein:
R1 is —C(═O)OR5, —C(═O)NR6R7, or —NR6R7;
R2 and R3 are each independently alkyl or alkenyl;
R4 is:
H,
cycloalkyl,
heterocycloalkyl, or
C1-10 alkyl which is substituted with at least one:
substituted aryl, wherein at least one of said aryl substituents is other than OH, nitro, amino, halo, CN, CH2CN, CONH2, C1-4 alkyl, C1-4 alkoxy, or C1-5 alkanoyl (which latter three groups are optionally substituted by one or more halo atoms),
aryloxyaryl,
-aryl-N(H)Rb,
-aryl-N(Rb)Rb,
heteroarylaryl,
alkoxyaryl, wherein the carbon chain of said alkoxy is interrupted by a nitrogen atom,
substituted alkoxyaryl, provided that when one or more substituents are present on the alkoxy group, at least one of said substituents is other than halo,
substituted cycloalkyl,
RS(═O)p substituted heteroaryl,
RS(═O)p substituted heterocycloalkyl,
RS(═O)p substituted aryl,
heterocycloalkylheteroaryl,
heteroarylheteroaryl,
bicycloalkyl,
bicycloalkenyl,
carboxy,
—CO2Ra,
—C(═O)N(R6a)—R6b—CO2H,
—C(═O)N(R6a)—R6b—CO2R,
—C(═O)N(R6a)—R6b—C(═O)NR7aR7b,
—N(R7c)C(═O)R7d,
—N(R7c)S(═O)2R7d,
aralkoxyaryl,
substituted arylheteroaryl, or
substituted alkoxyheteroaryl, provided that when one or more substituents are present on the alkoxy group, at least one of said substituents is other than halo;
p is 0, 1, or 2;
R is alkyl, aralkyl, or aryl;
Ra is H, alkyl, alkenyl, cycloalkyl, aryl, or heteroaryl, provided that Ra is not C1-6 alkyl;
each Rb is independently alkyl, cycloalkyl, aralkyl, or aryl,
R6a is H, alkyl, aralkyl, cycloalkyl, alkenyl, aryl, heteroaralkyl, or heteroaryl;
R6b is lower alkylene, or lower aralkylene or, together with the nitrogen atom to which they are attached, R6a and R6b form a 4- to 7-membered heterocycloalkyl ring;
R7a and R7b are each independently H, alkyl, cycloalkyl, heterocycloalkyl, heteroaryl, aralkyl, or aryl, or together with the nitrogen atom to which they are attached, R7a and R7b form a 4- to 7-membered heterocycloalkyl ring, provided that at least one of R7a and R7b is other than H;
R7c and R7d are each independently H, alkyl, cycloalkyl, heterocycloalkyl, heteroaryl, aralkyl, or aryl;
R5 is H or alkyl; and
each R6 and R7 is independently H, alkyl, or —C(═O)R, or, together with the nitrogen atom to which they are attached, R6 and R7 form a 4- to 7-membered heterocycloalkyl ring, provided that no more than one of R6 and R7 is —C(═O)R, and provided that when R1 is NR6R7, R4 can also be aralkyl;
provided that when R4 is H and R2 and R3 are each independently alkyl, then R1 is —C(═O)NR6R7 or —NR6R7, wherein at least one of R6 and R7 is —C(═O)R, or, R6 and R7 taken together with the nitrogen atom to which they are attached, form a 4- to 7-membered heterocycloalkyl ring;
or a stereoisomer, prodrug, pharmaceutically acceptable salt, hydrate, solvate, acid salt hydrate, N-oxide or isomorphic crystalline form thereof, provided that R2 and R3 are not in the cis stereoisomer conformation when both R2 and R3 are methyl.

### Claim 2 (depends on 1)

A compound according to claim 1, wherein said compound is a compound of formula Ia:

### Claim 3 (depends on 2)

A compound according to claim 2, wherein R2 is methyl.

### Claim 4 (depends on 3)

A compound according to claim 3, wherein R3 is methyl.

### Claim 5 (depends on 4)

A compound according to claim 4, wherein said compound is a compound of formula IIa:
wherein:
R8 is alkyl, aralkyl, cycloalkyl, alkylcycloalkyl, aryl, heteroaryl, or heteroaralkyl;
R9 is H, alkyl, alkenyl, cycloalkyl, aryl, or heteroaryl provided that R9 is not C1-6 alkyl; and
n is an integer from 1 to 3.

### Claim 6 (depends on 5)

A compound according to claim 5, wherein said compound is a compound of formula IIIa:

### Claim 7

A compound selected from the group consisting of:
3-(3R,4R-dimethyl-piperidin-4-yl)-benzoic acid;
3-(3R,4R-dimethyl-[1,4′]bipiperidinyl-4-yl)-benzoic acid; and
3-(3R,4R-dimethyl-piperidin-4-yl)-benzamide;
or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 1)

A pharmaceutical composition, comprising:
a pharmaceutically acceptable carrier; and
a therapeutically effective amount of a compound according to claim 1.

### Claim 9 (depends on 8)

A pharmaceutical composition according to claim 8, further comprising a therapeutically effective amount of at least one opioid.

### Claim 10 (depends on 9)

A pharmaceutical composition according to claim 9, wherein said opioid is selected from alfentanil, buprenorphine, butorphanol, codeine, dezocine, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, levorphanol, meperidine (pethidine), methadone, morphine, nalbuphine, oxycodone, oxymorphone, pentazocine, propiram, propoxyphene, sufentanil, tramadol or mixtures thereof.

### Claim 11 (depends on 1)

A method for preventing or treating gastrointestinal dysfunction, comprising the step of:
administering to a patient in need thereof, an effective amount of a compound according to claim 1.

### Claim 12 (depends on 1)

A method for preventing or treating ileus, comprising the step of:
administering to a patient in need thereof, an effective amount of a compound according to claim 1.

### Claim 13 (depends on 1)

A method for treating or preventing a side effect associated with an opioid, comprising the step of:
administering to a patient in need thereof, an effective amount of a compound according to claim 1.

### Claim 14 (depends on 13)

A method according to claim 13, further comprising administering to the patient an effective amount of at least one opioid.

### Claim 15 (depends on 13)

A method according to claim 13, wherein said side effect is selected from constipation, nausea or vomiting.

### Claim 16 (depends on 13)

A method according to claim 13, wherein said administering step occurs before, during or after a step of administering at least one opioid.

### Claim 17 (depends on 1)

A method of preventing or treating pain, comprising the step of:
administering to a patient in need thereof, an effective amount of an opioid; and
an effective amount of a compound according to claim 1.

### Claim 18 (depends on 14)

A method according to claim 14, wherein said opioid is selected from alfentanil, buprenorphine, butorphanol, codeine, dezocine, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, levorphanol, meperidine (pethidine), methadone, morphine, nalbuphine, oxycodone, oxymorphone, pentazocine, propiram, propoxyphene, sufentanil, tramadol or mixtures thereof.

### Claim 19 (depends on 17)

A method according to claim 17, wherein said opioid is selected from alfentanil, buprenorphine, butorphanol, codeine, dezocine, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, levorphanol, meperidine (pethidine), methadone, morphine, nalbuphine, oxycodone, oxymorphone, pentazocine, propiram, propoxyphene, sufentanil, tramadol or mixtures thereof.

### Claim 20 (depends on 7)

A pharmaceutical composition, comprising:
a pharmaceutically acceptable carrier; and
a therapeutically effective amount of a compound according to claim 7.

### Claim 21 (depends on 20)

A pharmaceutical composition according to claim 20, further comprising a therapeutically effective amount of at least one opioid.

### Claim 22 (depends on 21)

A pharmaceutical composition according to claim 21, wherein said opioid is selected from alfentanil, buprenorphine, butorphanol, codeine, dezocine, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, levorphanol, meperidine (pethidine), methadone, morphine, nalbuphine, oxycodone, oxymorphone, pentazocine, propiram, propoxyphene, sufentanil, tramadol or mixtures thereof.

### Claim 23 (depends on 7)

A method for preventing or treating gastrointestinal dysfunction, comprising the step of:
administering to a patient in need thereof, an effective amount of a compound according to claim 7.

### Claim 24 (depends on 7)

A method for preventing or treating ileus, comprising the step of:
administering to a patient in need thereof, an effective amount of a compound according to claim 7.

### Claim 25 (depends on 7)

A method for treating or preventing a side effect associated with an opioid, comprising the step of:
administering to a patient in need thereof, an effective amount of a compound according to claim 7.

### Claim 26 (depends on 25)

A method according to claim 25, further comprising administering to the patient an effective amount of at least one opioid.

### Claim 27 (depends on 25)

A method according to claim 25, wherein said side effect is selected from constipation, nausea or vomiting.

### Claim 28 (depends on 25)

A method according to claim 25, wherein said administering step occurs before, during or after a step of administering at least one opioid.

### Claim 29 (depends on 7)

A method of preventing or treating pain, comprising the step of:
administering to a patient in need thereof, an effective amount of an opioid; and
an effective amount of a compound according to claim 7.

### Claim 30 (depends on 29)

A method according to claim 29, wherein said opioid is selected from alfentanil, buprenorphine, butorphanol, codeine, dezocine, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, levorphanol, meperidine (pethidine), methadone, morphine, nalbuphine, oxycodone, oxymorphone, pentazocine, propiram, propoxyphene, sufentanil, tramadol or mixtures thereof.

### Claim 31

A method of binding opioid receptors in a patient in need thereof, comprising the step of:
administering to said patient a therapeutically effective amount of a compound according of formula Ib:
wherein:
R1 is —C(═O)OR5, —C(═O)NR6R7, —NR6R7, or —CH2OR5;
R2 and R3 are each independently alkyl or alkenyl;
R4 is:
H,
cycloalkyl,
heterocycloalkyl, or
C1-10 alkyl which is substituted with at least one:
substituted aryl, wherein at least one of said aryl substituents is other than OH, nitro, amino, halo, CN, CH2CN, CONH2, C1-4 alkyl, C1-4 alkoxy, or C1-5 alkanoyl (which latter three groups are optionally substituted by one or more halo atoms),
aryloxyaryl,
-aryl-N(H)Rb,
-aryl-N(Rb)Rb,
heteroarylaryl,
alkoxyaryl, wherein the carbon chain of said alkoxy is interrupted by a nitrogen atom,
substituted alkoxyaryl, provided that when one or more substituents are present on the alkoxy group, at least one of said substituents is other than halo,
substituted cycloalkyl,
RS(═O)p substituted heteroaryl,
RS(═O)p substituted heterocycloalkyl,
RS(═O)p substituted aryl,
heterocycloalkylheteroaryl,
heteroarylheteroaryl,
bicycloalkyl,
bicycloalkenyl,
carboxy,
—CO2Ra,
—C(═O)N(R6a)—R6b—CO2H,
—C(═O)N(R6a)—R6b—CO2R,
—C(═O)N(R6a)—R6b—C(═O)NR7aR7b,
—N(R7c)C(═O)R7d,
—N(R7c)S(═O)2R7d,
aralkoxyaryl,
substituted arylheteroaryl, or
substituted alkoxyheteroaryl, provided that when one or more substituents are present on the alkoxy group, at least one of said substituents is other than halo;
p is 0, 1, or 2;
R is alkyl, aralkyl, or aryl;
Ra is H, alkyl, alkenyl, cycloalkyl, aryl, or heteroaryl, provided that Ra is not C1-6 alkyl;
each Rb is independently alkyl, cycloalkyl, aralkyl, or aryl,
R6a is H, alkyl, aralkyl, cycloalkyl, alkenyl, aryl, heteroaralkyl, or heteroaryl;
R6b is lower alkylene, or lower aralkylene or, together with the nitrogen atom to which they are attached, R6a and R6b form a 4- to 7-membered heterocycloalkyl ring;
R7a and R7b are each independently H, alkyl, cycloalkyl, heterocycloalkyl, heteroaryl, aralkyl, or aryl, or together with the nitrogen atom to which they are attached, R7a and R7b form a 4- to 7-membered heterocycloalkyl ring, provided that at least one of R7a and R7b is other than H;
R7c and R7d are each independently H, alkyl, cycloalkyl, heterocycloalkyl, heteroaryl, aralkyl, or aryl;
R5 is H or alkyl; and
each R6 and R7 is independently H, alkyl, or —C(═O)R, or, together with the nitrogen atom to which they are attached, R6 and R7 form a 4- to 7-membered heterocycloalkyl ring, provided that no more than one of R6 and R7 is —C(═O)R, and provided that when R1 is NR6R7, R4 can also be aralkyl;
or a stereoisomer, prodrug, pharmaceutically acceptable salt, hydrate, solvate, acid salt hydrate, N-oxide or isomorphic crystalline form thereof, provided that R2 and R3 are not in the cis stereoisomer conformation when both R2 and R3 are methyl.

### Claim 32 (depends on 31)

A method according to claim 31, wherein said compound binds μ opioid receptors.

### Claim 33 (depends on 32)

A method according to claim 32, wherein said μ opioid receptors are located in the central nervous system.

### Claim 34 (depends on 32)

A method according to claim 32, wherein said μ opioid receptor are located peripherally to the central nervous system.

### Claim 35 (depends on 31)

A method according to claim 31, wherein said compound binds κ opioid receptors.

### Claim 36 (depends on 35)

A method according to claim 35, wherein said κ opioid receptors are located in the central nervous system.

### Claim 37 (depends on 35)

A method according to claim 35, wherein said κ opioid receptors are located peripherally to the central nervous system.

### Claim 38 (depends on 31)

A method according to claim 31, wherein said binding antagonizes the activity of said opioid receptors.

### Claim 39 (depends on 31)

A method according to claim 31, wherein said compound exhibits activity toward said opioid receptors.

### Claim 40 (depends on 31)

A method according to claim 31, wherein said compound does not substantially cross the blood-brain barrier.

### Claim 41 (depends on 31)

A method according to claim 31, wherein said patient is in need of prevention or treatment of a condition or disease caused by an opioid.

### Claim 42 (depends on 41)

A method according to claim 41, wherein said opioid is endogenous.

### Claim 43 (depends on 41)

A method according to claim 41, wherein said opioid is exogenous.

### Claim 44

A pharmaceutical composition, comprising:
a pharmaceutically acceptable carrier; and
a therapeutically effective amount of a compound of formula Ic:
wherein:
R1 is —C(═O)OR5, —C(═O)NR6R7, —NR6R7, or —CH2OR5;
R2 and R3 are each independently alkyl or alkenyl;
R5 is H or alkyl;
each R6 and R7 is independently H, alkyl, or —C(═O)R, or, together with the nitrogen atom to which they are attached, R6 and R7 form a 4- to 7-membered heterocycloalkyl ring, provided that no more than one of R6 and R7 is —C(═O)R; and
R is alkyl, aralkyl, or aryl;
or a stereoisomer, prodrug, pharmaceutically acceptable salt, hydrate, solvate, acid salt hydrate, or N-oxide thereof, provided that R2 and R3 are not in the cis stereoisomer conformation when both R2 and R3 are methyl.

### Claim 45 (depends on 44)

A pharmaceutical composition according to claim 44, further comprising a therapeutically effective amount of at least one opioid.

### Claim 46 (depends on 45)

A pharmaceutical composition according to claim 45, wherein said opioid is selected from alfentanil, buprenorphine, butorphanol, codeine, dezocine, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, levorphanol, meperidine (pethidine), methadone, morphine, nalbuphine, oxycodone, oxymorphone, pentazocine, propiram, propoxyphene, sufentanil, tramadol or mixtures thereof.

### Claim 47

A method for preventing or treating gastrointestinal dysfunction, comprising the step of:
administering to a patient in need thereof an effective amount of a compound of formula Ic:
wherein:
R1 is —C(═O)OR5, —C(═O)NR6R7, —NR6R7, or —CH2OR5;
R2 and R3 are each independently alkyl or alkenyl;
R5 is H or alkyl;
each R6 and R7 is independently H, alkyl, or —C(═O)R, or, together with the nitrogen atom to which they are attached, R6 and R7 form a 4- to 7-membered heterocycloalkyl ring, provided that no more than one of R6 and R7 is —C(═O)R and
R is alkyl, aralkyl, or aryl;
or a stereoisomer, prodrug, pharmaceutically acceptable salt, hydrate, solvate, acid salt hydrate, or N-oxide thereof, provided that R2 and R3 are not in the cis stereoisomer conformation when both R2 and R3 are methyl.

### Claim 48

A method for preventing or treating ileus, comprising the step of:
administering to a patient in need thereof an effective amount of a compound of formula Ic
wherein:
R1 is —C(═O)OR5, —C(═O)NR6R7, —NR6R7, or —CH2OR5;
R2 and R3 are each independently alkyl or alkenyl;
R5 is H or alkyl;
each R6 and R7 is independently H, alkyl, or —C(═O)R, or, together with the nitrogen atom to which they are attached, R6 and R7 form a 4- to 7-membered heterocycloalkyl ring, provided that no more than one of R6 and R7 is —C(═O)R; and
R is alkyl, aralkyl, or aryl;
or a stereoisomer, prodrug, pharmaceutically acceptable salt, hydrate, solvate, acid salt hydrate, or N-oxide thereof, provided that R2 and R3 are not in the cis stereoisomer conformation when both R2 and R3 are methyl.

### Claim 49

A method for treating or preventing a side effect associated with an opioid, comprising the step of:
administering to a patient in need thereof an effective amount of a compound of formula Ic
wherein:
R1 is —C(═O)OR5, —C(═O)NR6R7, —NR6R7, or —CH2OR5;
R2 and R3 are each independently alkyl or alkenyl;
R5 is H or alkyl;
each R6 and R7 is independently H, alkyl, or —C(═O)R, or, together with the nitrogen atom to which they are attached, R6 and R7 form a 4- to 7-membered heterocycloalkyl ring, provided that no more than one of R6 and R7 is —C(═O)R; and
R is alkyl, aralkyl, or aryl;
or a stereoisomer, prodrug, pharmaceutically acceptable salt, hydrate, solvate, acid salt hydrate, or N-oxide thereof, provided that R2 and R3 are not in the cis stereoisomer conformation when both R2 and R3 are methyl.

### Claim 50 (depends on 49)

A method according to claim 49, further comprising administering to the patient an effective amount of at least one opioid.

### Claim 51 (depends on 49)

A method according to claim 49, wherein said side effect is selected from constipation, nausea or vomiting.

### Claim 52 (depends on 49)

A method according to claim 49, wherein said administering step occurs before, during or after a step of administering at least one opioid.

### Claim 53

A method of preventing or treating pain, comprising the step of:
administering to a patient in need thereof an effective amount of an opioid; and
an effective amount of a compound of formula Ic:
wherein:
R1 is —C(═O)OR5, —C(═O)NR6R7, —NR6R7, or —CH2OR5;
R2 and R3 are each independently alkyl or alkenyl;
R5 is H or alkyl;
each R6 and R7 is independently H, alkyl, or —C(═O)R, or, together with the nitrogen atom to which they are attached, R6 and R7 form a 4- to 7-membered heterocycloalkyl ring, provided that no more than one of R6 and R7 is —C(═O)R; and
R is alkyl, aralkyl, or aryl;
or a stereoisomer, prodrug, pharmaceutically acceptable salt, hydrate, solvate, acid salt hydrate, or N-oxide thereof, provided that R2 and R3 are not in the cis stereoisomer conformation when both R2 and R3 are methyl.

### Claim 54 (depends on 50)

A method according to claim 50, wherein said opioid is selected from alfentanil, buprenorphine, butorphanol, codeine, dezocine, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, levorphanol, meperidine (pethidine), methadone, morphine, nalbuphine, oxycodone, oxymorphone, pentazocine, propiram, propoxyphene, sufentanil, tramadol or mixtures thereof.

### Claim 55 (depends on 53)

A method according to claim 53, wherein said opioid is selected from alfentanil, buprenorphine, butorphanol, codeine, dezocine, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, levorphanol, meperidine (pethidine), methadone, morphine, nalbuphine, oxycodone, oxymorphone, pentazocine, propiram, propoxyphene, sufentanil, tramadol or mixtures thereof.
